Canadian trade union Unifor said roughly 4,500 of its members have been temporarily laid off because of the GM strike so far.Autosread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
Morrison and Trump were expected to discuss a range of issues during a bilateral meeting Friday morning, including the ongoing U.S.-China trade war and the rising tensions in...Politicsread more
Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Some businesses, mostly small to midsize companies, are providing workers with paid time off to join the global climate strike, while others are shutting down operations...Weather & Natural Disastersread more
FedEx's earnings disappointment and outlook warning earlier this week were a "wake-up call," says the "Mad Money" host.Investingread more
* Defendants to face claims they conspired to cause opioid crisis
* Purdue Pharma, J&J, CVS, Walgreen, Walmart among defendants
* Trial scheduled for Oct. 21 even as judge urges settlement (Adds Johnson & Johnson, Mallinckrodt as defendants, PIX available)
Sept 3 (Reuters) - A U.S. judge on Tuesday rejected efforts by major drugmakers, pharmacies and distributors to dismiss claims that they caused the nation's opioid crisis, clearing the way for a scheduled landmark trial even as he pushes for a nationwide settlement.
U.S. District Judge Dan Polster, who oversees roughly 2,000 opioid lawsuits by states, counties and cities, said the plaintiffs can try to prove that drugmakers' deceptive marketing of the painkillers caused a harmful, massive increase in supply that pharmacies and distributors did not do enough to stop.
"A factfinder could reasonably infer that these failures were a substantial factor in producing the alleged harm suffered by plaintiffs," the Cleveland-based judge wrote.
The ruling was among seven decisions and orders totaling 80 pages from Polster ahead of a scheduled Oct. 21 trial by two Ohio counties against Purdue Pharma, the OxyContin maker accused of fueling the epidemic, and several other defendants.
Polster also refused to dismiss civil conspiracy claims against drugmakers, pharmacies and distributors, and said federal law did not preempt much of the plaintiffs' case.
Other defendants included the drugmakers Endo International Plc and Johnson & Johnson; pharmacy operators CVS Health Corp, Rite Aid Corp, Walgreens Boots Alliance Inc and Walmart Inc; and distributors AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.
Polster also refused to dismiss a variety of claims against generic drugmakers Allergan Plc, Mallinckrodt Plc and Teva Pharmaceutical Industries Ltd.
Opioid addiction claimed roughly 400,000 lives in the United States from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
Critics of the industry said opioid makers hid the addiction and abuse risks of prolonged use from consumers.
Rite Aid's lawyers declined to comment. Lawyers for other major defendants did not immediately respond to requests for comment.
Paul Hanly, a lawyer for the plaintiffs, said his clients were pleased that Polster "almost uniformly" agreed with their positions on the dismissal requests and whether to admit various testimony.
J&J has said it will appeal an Oklahoma judge's Aug. 26 order that it pay $572.1 million to that state for the company's role in the opioid epidemic.
Purdue and its owners, the Sackler family, have been in talks on a possible $10 billion to $12 billion nationwide settlement of opioid claims, two people familiar with the matter said last week.
That accord could include a bankruptcy filing for the Stamford, Connecticut-based company. Purdue and the Sacklers have denied the allegations.
The case is In re National Prescription Opiate Litigation, U.S. District Court, Northern District of Ohio, No. 17-md-02804. (Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot)